Literature DB >> 22390034

[Study about eye complication of nasopharyngeal carcinoma].

Bing Lian1, Jiqun Wang, Weijun Zhang, Yanchun Shan.   

Abstract

OBJECTIVE: To explore the eye complication of nasopharyngeal carcinoma (NPC), to analysis the clinical manifestation, CT characteristics and pathological diagnosis of eye complications of NPC and to provide the base for early diagnosis of NPC.
METHOD: To retrospectively study of 82 cases eye complications in 562 cases NPC, to study their clinical manifestation, CT characteristics and pathological diagnosis. RESULT: The clinical studies showed that eye complication cases were occurred in 82 cases of 562 NPC cases (14.6%). Thirty-six cases in left and 37 cases in right eye, 9 cases in bilateral eyes. Sixty-five cases came from Guangdong, while the others 17 cases come from 5 provinces. There were 9 kinds of eye manifestation. CT appearances: 40 cases suffered from skull base distracted, 6 cases with orbit involved, 2 cases ( in left eyes) with orbit metastasis, 12 cases with nose-sinus involved, 68 case with parapharyngeal space involved, 49 cases with soft issue in wall of styloid process involved (there were many kind of shows in the same case, so the data were repeated in these cases).
CONCLUSION: There were multiplicity and complexity in eye complication of NPC. Ophthalmologists should think highly of these cases.

Entities:  

Mesh:

Year:  2011        PMID: 22390034

Source DB:  PubMed          Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 2096-7993


  2 in total

1.  The predictive value of serum lipids for eye metastases in male nasopharyngeal carcinoma patients.

Authors:  Zhen Xie; Yi Shao
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

2.  CYFRA21-1/TG ratio as an accurate risk factor to predict eye metastasis in nasopharyngeal carcinoma: A STROBE-compliant article.

Authors:  Sheng-Jia Peng; Chu-Feng Wang; Ya-Jie Yu; Chen-Yu Yu; Si-Yi Chen; Shi-Nan Wu; Si-Wen Tan; Jia-Xin Peng; Biao Li; Yi Shao
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.